Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Up 16.6% in June

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the recipient of a large increase in short interest in June. As of June 15th, there was short interest totalling 798,200 shares, an increase of 16.6% from the May 31st total of 684,800 shares. Currently, 7.3% of the company’s shares are sold short. Based on an average daily volume of 85,900 shares, the days-to-cover ratio is currently 9.3 days.

Institutional Investors Weigh In On Jasper Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in Jasper Therapeutics in the first quarter valued at $306,000. Concurrent Investment Advisors LLC acquired a new position in shares of Jasper Therapeutics during the first quarter valued at $599,000. Fernwood Investment Management LLC increased its holdings in shares of Jasper Therapeutics by 8.8% during the fourth quarter. Fernwood Investment Management LLC now owns 494,706 shares of the company’s stock valued at $390,000 after purchasing an additional 40,000 shares during the period. Ieq Capital LLC acquired a new position in shares of Jasper Therapeutics during the fourth quarter valued at $43,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Jasper Therapeutics during the first quarter valued at $2,343,000. 79.85% of the stock is currently owned by institutional investors.

Jasper Therapeutics Stock Performance

JSPR stock opened at $22.78 on Wednesday. The stock has a market capitalization of $343.07 million, a price-to-earnings ratio of -4.05 and a beta of 2.22. Jasper Therapeutics has a 1 year low of $4.00 and a 1 year high of $31.01. The stock’s fifty day moving average is $23.15 and its two-hundred day moving average is $19.79.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Tuesday, May 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.23. As a group, analysts predict that Jasper Therapeutics will post -4.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on JSPR shares. Royal Bank of Canada started coverage on shares of Jasper Therapeutics in a research report on Thursday, March 28th. They set an “outperform” rating and a $70.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $65.00 target price on shares of Jasper Therapeutics in a research note on Wednesday, May 15th. TD Cowen initiated coverage on Jasper Therapeutics in a research note on Monday, March 18th. They set an “outperform” rating for the company. Evercore ISI initiated coverage on Jasper Therapeutics in a research note on Wednesday, April 3rd. They set an “outperform” rating and a $65.00 price objective on the stock. Finally, Stifel Nicolaus initiated coverage on Jasper Therapeutics in a research note on Thursday, June 27th. They set a “buy” rating and a $86.00 price objective on the stock. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $67.00.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.